Macquarie Group Ltd. significantly reduced its stake in Salesforce Inc. by selling 1,256,401 shares, representing a 73.6% decrease in its position, and now holds 451,257 shares valued at $119.54 million. Despite institutional selling, Salesforce saw insider buying from directors David Blair Kirk and Laura Alber, who collectively purchased over 5,000 shares. The company has also announced a share repurchase program worth $25 billion and a quarterly dividend of $0.44 per share, while analysts maintain a "Moderate Buy" rating with an average price target of $259.26.

EPAM Systems stock appears to be an attractive investment opportunity due to its strong fundamentals, including an impressive cash flow yield of 10.6% and revenue growth of 14.2% over the last twelve months. The stock is currently trading at a significant discount to its 3-month, 1-year, and 2-year highs. While individual stock trades carry risks, the robust cash yield and multi-year valuation trough suggest a potential mean-reversion signal.

Trillium Asset Management LLC reduced its stake in First Solar, Inc. (NASDAQ:FSLR) by 17.3% during the fourth quarter, selling 29,767 shares and valuing its remaining 142,545 shares at $37.64 million. Meanwhile, other institutional investors like Vanguard Group Inc., Geode Capital Management LLC, Viking Global Investors LP, Amundi, and Norges Bank either increased their holdings or initiated new positions in the company. First Solar recently reported strong earnings, beating analyst estimates, and experienced insider selling by its CEO and another insider.

Macquarie Group Ltd. has significantly reduced its stake in Gilead Sciences, Inc. by 30.2% in the fourth quarter, selling 479,391 shares. Despite this reduction, Gilead Sciences remains a significant holding for Macquarie, accounting for 0.6% of its portfolio. Other institutional investors have shown varied activity, while analysts have provided a "Moderate Buy" consensus rating for Gilead with a target price of $156.93.

Trillium Asset Management LLC significantly reduced its holdings in Gilead Sciences, Inc. by 20.2% in the fourth quarter, selling nearly 20,000 shares. Despite this, other major institutional investors like Vanguard and Norges Bank increased their stakes, with institutional ownership of GILD remaining high at 83.67%. Gilead also reported strong quarterly earnings, surpassing analyst estimates, and declared an $0.82 quarterly dividend, indicating a 2.6% yield.

Trillium Asset Management LLC significantly reduced its stake in lululemon athletica inc. (NASDAQ:LULU) by 21.1% in the fourth quarter, selling 21,571 shares and now owning 80,825 shares valued at $17,024,000. Other institutions also adjusted their positions in the company, which saw its stock open at $118.77 on Friday and has a market cap of $14.09 billion. Despite recent negative analyst revisions and an average target price of $154.26, lululemon athletica reported strong quarterly earnings, beating analyst estimates, and has provided positive FY 2026 guidance.

ROI Financial Advisors LLC reduced its stake in NVIDIA (NASDAQ:NVDA) by 5.8% in the fourth quarter, though the stock remains its largest holding, valued at $12 million. Despite this cut, NVIDIA reported strong quarterly results with EPS of $1.87 and revenue of $81.62 billion, exceeding expectations and showing an 85.2% year-over-year increase. The company also announced an $80 billion share buyback program and raised its quarterly dividend to $0.25 per share, while analysts maintain a bullish "Buy" rating with an average target price of $305.67.

Klingenstein Fields & Co. LP reduced its stake in The Goldman Sachs Group by 2.1% in the fourth quarter, selling 1,681 shares. Despite insider selling activity, Goldman Sachs shows fundamental strength with boosted earnings, declared dividends, and overall "Hold" consensus from analysts. Several other institutional investors have also adjusted their positions in the company.

Rhenman & Partners Asset Management AB has invested $1.52 million in STERIS plc, purchasing 6,000 shares in the fourth quarter, contributing to institutional investors owning 94.69% of the stock. Despite this new investment and other institutional increases, STERIS recently saw notable insider selling by its CEO and a Director. The company reported slightly lower-than-estimated quarterly earnings per share but matched revenue expectations, and analysts currently rate the stock as a "Moderate Buy."

Rhenman & Partners Asset Management AB has decreased its stake in Stoke Therapeutics (NASDAQ:STOK) by 13.6% in the fourth quarter, reducing its holdings to 216,000 shares worth approximately $6.86 million. This comes alongside recent insider selling activity, with Barry Ticho and Jason Hoitt selling shares in March. Despite the reduction in institutional holdings and insider selling, Stoke Therapeutics surpassed earnings estimates, and analysts maintain a "Moderate Buy" rating with an average target price of $41.83.